Comparative Pharmacology
Head-to-head clinical analysis: AXUMIN versus TECHNETIUM TC 99M SESTAMIBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXUMIN versus TECHNETIUM TC 99M SESTAMIBI.
AXUMIN vs TECHNETIUM TC 99M SESTAMIBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
Technetium Tc 99m sestamibi is a cationic lipophilic complex that passively diffuses across cell membranes and accumulates in mitochondria due to the negative mitochondrial membrane potential. It is used as a myocardial perfusion imaging agent to visualize blood flow to the heart muscle.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
Myocardial imaging: 740-1110 MBq (20-30 mCi) IV bolus, single dose. Parathyroid imaging: 740-925 MBq (20-25 mCi) IV bolus, single dose.
None Documented
None Documented
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Terminal elimination half-life: approximately 6 hours (range 4–8 hours) for myocardial clearance. Delayed clearance may occur in patients with hepatic or renal impairment.
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Primarily renal: approximately 33% of injected dose excreted in urine within 8 hours, increasing to about 50% by 24 hours. Hepatic uptake with subsequent biliary excretion accounts for the remainder; fecal elimination is less than 2% of administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical